The University of Kansas Cancer Center Kansas City, Missouri
This presentation will review recent updates in the management of cervical cancer, with a focus on recurrent or metastatic disease. It will address the addition of pembrolizumab to first-line chemotherapy with or without bevacizumab as well as the use of the new molecular entity tisotumab vedotin in the second-line setting. The presentation will also touch on prevention and management of toxicities associated with these agents including immune-related adverse events, ocular toxicities and bleeding events.
Learning Objectives:
Identify which patients may benefit from the addition of pembrolizumab to first-line chemotherapy with or without bevacizumab for the treatment of recurrent or metastatic cervical cancer
Describe management strategies for immune-related adverse events
Discuss the use of tisotumab vedotin for recurrent or metastatic cervical cancer
Recognize common and serious adverse events associated with use of tisotumab vedotin